Perma-Fix Environmental Services

Perma-Fix operates three segments: Treatment Services, which processes mixed and hazardous waste at five licensed facilities; Services, which supplies on-site radiological personnel to DOE decommissioning sites; and Medical, which manages isotope disposal for hospitals. The Treatment segment generates recurring revenue from long-term government baseline contracts that typically span five to ten years, creating high visibility. However, substantial upside comes from task-order remediation surge work tied to specific DOE cleanup milestones, which makes quarterly results lumpy.

Perma-Fix holds permits under the Resource Conservation and Recovery Act for hazardous waste treatment and Atomic Energy Act licenses for radioactive material possession, transfer, and disposal at facilities in Tennessee and Washington. The Richland, Washington plant additionally holds a unique license to accept off-site transuranic and mixed waste from DOE legacy sites. Acquiring comparable licenses would require a new entrant to navigate EPA, NRC, and DOE approvals simultaneously, a multi-decade process.

Roughly two-thirds of revenue derives from U.S. federal government clients, primarily the DOE, Department of Defense, and the U.S. Navy. The remainder splits between commercial nuclear utilities — such as Exelon and Duke Energy — and medical and research institutions needing radioisotope disposal. The government proportion fluctuates depending on DOE budget allocation for environmental management, which has been increasing as legacy cleanup milestones approach statutory deadlines.

Perma-Fix Medical is a Polish-incorporated subsidiary developing technology to extract technetium-99m, a diagnostic imaging isotope, from aging molybdenum generators that would otherwise require costly long-term disposal. The business is pre-revenue and constitutes a call option on medical isotope supply-chain disruption, not a material earnings contributor today. The company has pursued European Medicines Agency cooperation to validate the technology and scale procurement channels.

The firm treats mixed low-level waste — combining hazardous constituents like heavy metals or solvents with radioactive isotopes — along with transuranic waste, sealed sources from medical and industrial users, and naturally occurring radioactive material from oil-and-gas and water-treatment activities. Treatment methods include macroencapsulating sludges in polymer resins, thermally desorbing volatile organics from contaminated soils, and stabilizing ash and debris in grout for permanent disposal at DOE-licensed repositories such as the Waste Isolation Pilot Plant.